Actos Bladder Cancer Lawsuit
Actos users file class action lawsuit against Takeda Pharmaceuticals

Two users of type II diabetes drug Actos have filed a class action lawsuit against Takeda Pharmaceuticals, the makers of the drug, and Eli Lilly, strategic partner to Takeda. Complaints were made that the drug company failed to properly research and warn about the Actos bladder cancer risk associated with the actos drug. Takeda Pharmaceuticals has been accused of purposely misrepresenting the harmful damages in order to maximize profits. A class action lawsuit has been filed on behalf of all users of the drug and is seeking financial compensation along with medical monitoring. If the complaint is certified, millions who have taken the actos drug may be covered.

Actos was released in July of 1999 and was intended for the purpose of increasing the body’s sensitivity to insulin. It has grown in popularity over the years and brought in revenues of $4.3 billion in 2010. However, French drug regulators forced a recall of the Actos medication in that same year, contributing the recall to an increasing number of bladder cancer cases causes by the Actos drug.

In December of this year, the U.S. Judicial Panel on Multidistrict Litigation is expecting to determine if the class action lawsuit, along with the 50 individual lawsuits filed against the company, should be centralized before one judge for pretrial proceedings.

If you or a loved one has taken Actos and suffered from bladder cancer, contact an Actos bladder cancer lawyer today.


About the Contributor

Related Posts